Crestor vs Losartan in Special Populations: A Head-to-Head Comparison

What Are Rosuvastatin and Losartan and Why Compare Them?

Rosuvastatin and losartan are both first-line cardiometabolic drugs, but they address different physiologic targets. Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, driving down LDL-C and stabilizing atherosclerotic plaque. Losartan blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone release, and renal efferent arteriole tone. A clinician would rarely ask "which one?" because the two drugs are complementary in most patients who need both.

The comparison becomes clinically meaningful in several specific situations: a patient who can tolerate only one new prescription at a time, a formulary that favors one over the other, or a population where one drug carries special warnings. The sections below address each of those scenarios by population.

Mechanism Differences That Drive Clinical Decisions

Rosuvastatin's LDL-lowering effect peaks at roughly 4 weeks and is largely independent of dietary fat or sodium intake. The FDA-approved label notes that 10 mg/day produces a 46% mean reduction in LDL-C and that 40 mg/day produces a 55% reduction. Losartan's antihypertensive effect depends on renin-angiotensin-aldosterone system (RAAS) activity and is enhanced by sodium restriction and diuretic co-administration.

Why "Switching" Is Usually the Wrong Frame

A patient on rosuvastatin for hypercholesterolemia who also develops hypertension does not switch to losartan. Losartan has no meaningful LDL-lowering effect. Similarly, a patient on losartan for hypertension who develops dyslipidemia does not switch to rosuvastatin. Rosuvastatin has no antihypertensive effect. The clinical question is almost always about adding the second drug, adjusting doses, or managing the interaction profile.

Head-to-Head Evidence: JUPITER vs LIFE

No randomized controlled trial has directly compared rosuvastatin to losartan. The key trials tested each drug against placebo in different populations, so any comparison is indirect.

JUPITER Trial: Rosuvastatin in Primary Prevention

JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 adults with LDL-C <130 mg/dL but elevated high-sensitivity CRP (hsCRP ≥2.0 mg/L). Rosuvastatin 20 mg/day reduced the primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death) by 44% vs placebo (HR 0.56; 95% CI 0.46 to 0.69; P<0.001). The trial was stopped early at a median of 1.9 years due to overwhelming benefit.

JUPITER also showed a 54% relative risk reduction in MI and a 48% reduction in stroke. The number needed to treat (NNT) to prevent one primary event over 2 years was 95.

LIFE Trial: Losartan in Hypertensive Patients With LVH

LIFE (Losartan Intervention For Endpoint reduction in hypertension) enrolled 9,193 patients aged 55 to 80 with hypertension and electrocardiographic left ventricular hypertrophy (LVH). Losartan 50 to 100 mg/day reduced the composite of CV death, MI, and stroke by 13% vs atenolol (RR 0.87; 95% CI 0.77 to 0.98; P=0.021) after 4.8 years of follow-up. The trial was an active comparator design, not placebo-controlled, which is a key limitation for cross-trial comparisons.

LIFE also demonstrated a 25% relative risk reduction in stroke specifically (P=0.001) and a 13% reduction in new-onset diabetes (P=0.001) compared with atenolol.

What the Cross-Trial Comparison Can and Cannot Tell Us

Because JUPITER enrolled patients with near-normal LDL-C and elevated inflammation while LIFE enrolled patients with hypertension and LVH, the populations are essentially non-overlapping. An indirect comparison using network meta-analysis methodology would require adjusting for baseline cardiovascular risk, and no published network meta-analysis has done so directly for this pair of drugs. The practical takeaway: both drugs reduce major adverse cardiovascular events in their respective target populations, and the ACC/AHA guidelines treat them as complementary rather than competing agents. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease recommends statin therapy and blood pressure control as separate, additive interventions.

Special Population 1: Chronic Kidney Disease

CKD changes the risk-benefit profile of both drugs in ways that matter for prescribing decisions.

Rosuvastatin in CKD

The SHARP trial (Study of Heart and Renal Protection, N=9,270) assigned patients with CKD to simvastatin 20 mg plus ezetimibe 10 mg vs placebo. While that trial did not use rosuvastatin, the broader statin CKD literature supports benefit. A 2014 Cochrane review of statins in CKD (49 trials, N=45,285) found statins reduced all-cause mortality (RR 0.79; 95% CI 0.69 to 0.91) and cardiovascular mortality (RR 0.77; 95% CI 0.69 to 0.87) in patients with CKD not on dialysis.

The FDA label for rosuvastatin specifies a maximum dose of 10 mg/day in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) who are not on hemodialysis. In patients on dialysis, rosuvastatin's prescribing information states the drug is not recommended due to lack of data.

Losartan in CKD and Diabetic Nephropathy

Losartan has the stronger evidence base in CKD specifically caused by type 2 diabetes. The RENAAL trial (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan, N=1,513) compared losartan 50 to 100 mg/day vs placebo on top of conventional antihypertensive therapy. Losartan reduced the composite of doubling of serum creatinine, ESRD, or death by 16% (P=0.022) and reduced ESRD alone by 28% (P=0.002). The 24-hour urinary protein-to-creatinine ratio fell 35% with losartan vs 0% with placebo at 6 months.

The IDNT trial (Irbesartan Diabetic Nephropathy Trial) used a related ARB (irbesartan) with similar results, reinforcing the class effect. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD recommends ACE inhibitor or ARB therapy as first-line in patients with diabetic kidney disease and albuminuria >300 mg/g.

Key Dosing Table for CKD

| Drug | eGFR 30 to 59 | eGFR <30 (not dialysis) | On Dialysis | |---|---|---|---| | Rosuvastatin | No adjustment | Max 10 mg/day | Not recommended | | Losartan | No adjustment | Use with caution; monitor K+ | Use with caution; monitor K+ |

Special Population 2: Type 2 Diabetes

Both drugs reduce cardiovascular events in patients with type 2 diabetes, though through different pathways.

Rosuvastatin in Type 2 Diabetes

The CARDS trial (Collaborative Atorvastatin Diabetes Study, N=2,838) used atorvastatin rather than rosuvastatin, but post-hoc analyses of JUPITER found that among the 1,501 patients who developed diabetes during follow-up, rosuvastatin still reduced cardiovascular events. A 2010 analysis published in The Lancet confirmed that statins reduce vascular events in diabetic patients at a rate of 21% per 1 mmol/L LDL reduction, consistent across statin classes.

The ADA Standards of Care in Diabetes 2024 recommend high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) for all adults with type 2 diabetes aged 40 to 75 with an LDL-C ≥70 mg/dL or established ASCVD.

A notable caution: both JUPITER and a meta-analysis by Sattar et al. (N=91,140) found that statin use was associated with a 9% increased risk of new-onset type 2 diabetes. Rosuvastatin's cardiovascular benefit far exceeds this risk in high-risk populations, but the signal warrants monitoring fasting glucose annually in patients on high-intensity statin therapy.

Losartan in Type 2 Diabetes

The LIFE diabetic subgroup (N=1,195) showed that losartan reduced the primary composite endpoint by 24.5% vs atenolol (P=0.031) in patients with diabetes. The diabetic subgroup benefited more than the overall LIFE population, with a 37% relative risk reduction in CV death specifically.

Beyond LIFE, the RENAAL data confirmed losartan's renal-protective role in type 2 diabetes. The JNC 8 guideline and the ADA both recommend ACE inhibitors or ARBs as preferred antihypertensives in patients with diabetes and proteinuria. Losartan 100 mg/day is the dose most consistently associated with renoprotection in trials.

Special Population 3: Elderly Patients (Age &ge;65)

Age-related pharmacokinetic and pharmacodynamic changes affect both drugs, though differently.

Rosuvastatin Pharmacokinetics in the Elderly

Rosuvastatin's AUC is approximately 50% higher in elderly patients (≥65 years) compared with younger adults, according to the FDA label. This means the same dose produces higher plasma concentrations. The risk of myopathy, including rhabdomyolysis, increases with age, particularly above 65. The 2022 ACC Expert Consensus Decision Pathway on Statin Safety recommends starting elderly patients on low-to-moderate intensity statin therapy (e.g., rosuvastatin 5 to 10 mg) and titrating based on response and tolerability.

Losartan in Elderly Hypertensive Patients

Elderly patients with isolated systolic hypertension tolerate ARBs well, with a lower risk of dry cough than ACE inhibitors and a lower risk of orthostatic hypotension than alpha-blockers or older diuretics at standard doses. The LIFE trial's mean age was 66.9 years, lending direct evidence to losartan's use in this population. The trial showed consistent benefit across age subgroups. A 2019 Cochrane review of antihypertensives in the elderly found ARBs reduced stroke and CV events with favorable tolerability.

Renal function declines with age, so monitoring eGFR and serum potassium every 6 to 12 months during losartan therapy is appropriate in patients over 70. The standard starting dose of 50 mg/day can be titrated to 100 mg/day if the BP target (<130/80 mmHg per the 2017 ACC/AHA Hypertension Guideline) is not met.

Special Population 4: Asian Patients

The FDA label for rosuvastatin contains a specific pharmacogenomic warning for patients of Asian ancestry.

Rosuvastatin Dosing in Asian Patients

Pharmacokinetic studies show that Asian patients (including those of South Asian, East Asian, and Southeast Asian descent) have approximately 2-fold higher rosuvastatin plasma concentrations (AUC) compared with Caucasian patients at equivalent doses. The FDA prescribing information recommends a starting dose of 5 mg/day in Asian patients, with caution about escalating beyond 20 mg/day unless LDL targets are not achievable at lower doses.

This is one of the few statin dose adjustments based on ethnicity with formal FDA labeling support.

Losartan Pharmacokinetics in Asian Patients

No analogous FDA label warning exists for losartan in Asian patients. Losartan is metabolized by CYP2C9 to its active metabolite E-3174, which is 10 to 40 times more potent. CYP2C9 poor metabolizers (∼1 to 3% of the general population, slightly higher in some Asian subgroups) may have lower E-3174 exposure and reduced antihypertensive effect. A pharmacogenomic review published in Clinical Pharmacology and Therapeutics found that CYP2C9*3 carriers had significantly lower E-3174 AUC, though the clinical consequence at standard 50 to 100 mg doses is modest.

Special Population 5: Pregnancy and Women of Childbearing Age

Both drugs carry pregnancy contraindications, but for different mechanistic reasons.

Rosuvastatin in Pregnancy

Statins are contraindicated in pregnancy. Cholesterol is required for fetal development, and HMG-CoA reductase inhibition during organogenesis carries theoretical teratogenic risk. The FDA updated statin labeling in 2021 to replace the former Category X designation with a more nuanced warning acknowledging that isolated case reports do not confirm teratogenicity but that use during pregnancy should be avoided unless benefits clearly outweigh risks in a specific clinical scenario (e.g., homozygous familial hypercholesterolemia with imminent cardiovascular risk).

Women of childbearing age who are prescribed rosuvastatin should be counseled to use contraception and to discontinue the drug immediately if pregnancy is discovered.

Losartan in Pregnancy

Losartan and all ARBs are absolutely contraindicated in pregnancy. The FDA black box warning states that when pregnancy is detected, losartan should be discontinued as soon as possible. ARBs can cause fetal renal dysplasia, oligohydramnios, neonatal renal failure, skull hypoplasia, and death when used in the second or third trimester. This risk is mechanistic and well-established. The contraindication is absolute.

Drug Interactions and Combination Safety

When a patient takes both rosuvastatin and losartan, the combination is pharmacokinetically benign. The two drugs do not share metabolic pathways that would cause competitive inhibition or induction.

CYP450 Profile and Interaction Risk

Rosuvastatin is minimally metabolized by CYP2C9 (roughly 10% of elimination) and is primarily cleared renally and via OATP1B1/1B3 transporters. Losartan is a CYP2C9 substrate. Strong CYP2C9 inhibitors (fluconazole, amiodarone) can raise losartan exposure. A drug interaction study found fluconazole increased losartan AUC by approximately 69% and reduced E-3174 formation, potentially blunting the antihypertensive response. Prescribers combining losartan with azole antifungals or amiodarone should monitor blood pressure more closely.

Rosuvastatin's primary interaction risk is with OATP1B1/1B3 inhibitors such as cyclosporine (which raises rosuvastatin AUC approximately 7-fold) and gemfibrozil (which raises AUC approximately 2-fold). These interactions are not shared with losartan.

Hyperkalemia Risk With Losartan Combinations

Losartan raises serum potassium by blocking aldosterone. The combination of losartan with potassium-sparing diuretics, trimethoprim, or other RAASblocking agents (ACE inhibitors, direct renin inhibitors) significantly increases hyperkalemia risk. A population-based study in BMJ (N=1,105,994) found that co-prescribing ARBs with trimethoprim increased sudden death risk 1.38-fold (95% CI 1.09 to 1.74). Rosuvastatin does not contribute to potassium dysregulation.

Should You Switch From Crestor to Losartan?

The short answer is no, in most cases. Switching from rosuvastatin to losartan makes physiologic sense only if a prescriber has made an error in the original indication.

A structured decision framework helps clarify when each drug is appropriate:

Step 1. Confirm the primary indication. If the patient's primary problem is elevated LDL-C or high ASCVD risk without hypertension, rosuvastatin is the correct first-line agent. Losartan will not address dyslipidemia.

Step 2. Assess for concurrent hypertension or proteinuria. If blood pressure is ≥130/80 mmHg or urinary albumin-to-creatinine ratio is >30 mg/g, add losartan rather than substitute it.

Step 3. Check for statin intolerance. A patient with confirmed statin myopathy (CK >10x ULN) who cannot tolerate any statin may need a non-statin LDL-lowering agent (ezetimibe, bempedoic acid, or a PCSK9 inhibitor) rather than losartan. Losartan will not compensate for the loss of LDL-C reduction.

Step 4. Evaluate special population considerations. In a patient with Asian ancestry, consider dose reduction rather than switching. In a pregnant patient, both drugs must be discontinued. In a CKD patient with diabetic nephropathy, losartan is the preferred agent for renal protection while the statin question is addressed separately based on eGFR.

Step 5. Address formulary or cost barriers directly. If cost drives the question, generic rosuvastatin is available at $10 to 20/month at most pharmacies, and generic losartan is similarly priced. GoodRx pricing data and the patient's plan formulary should be checked before making any change.

Monitoring Parameters Side by Side

| Parameter | Rosuvastatin | Losartan | |---|---|---| | Baseline LFTs | Yes (once) | Not required | | CK at baseline | If high-risk for myopathy | Not required | | Lipid panel follow-up | 4 to 12 weeks after initiation or dose change | Not applicable | | Blood pressure | Not applicable | 2 to 4 weeks after initiation or dose change | | Serum creatinine and eGFR | Annually in CKD | Every 3 to 6 months in CKD | | Serum potassium | Not required | Every 3 to 6 months in CKD or with diuretics | | Blood glucose | Annually in high-risk patients (statin-diabetes signal) | Not required |

The ACC/AHA 2018 Cholesterol Guideline recommends a fasting lipid panel 4 to 12 weeks after rosuvastatin initiation and every 3 to 12 months thereafter to confirm adherence and response.

Cost, Access, and Formulary Considerations

Generic rosuvastatin became available in the United States in 2016 and has substantially reduced costs. FDA generic drug approval data confirms multiple generic manufacturers. A 30-day supply of generic rosuvastatin 10 mg costs approximately $10 to 25 at retail pharmacies.

Generic losartan has been available since 2010 and is similarly priced, with 30-day supplies of losartan 50 mg available for $8 to 15. Both drugs are on virtually all Tier 1 or Tier 2 formulary lists for commercial and Medicare Part D plans, removing cost as a meaningful differentiator between the two.

The 2022 ACC Chest Pain Guideline and related documents consistently treat statins and ARBs as complementary investments in cardiovascular risk reduction, not as alternatives competing for one prescription slot.